Close

Mind Medicine (MNMD) Granted FDA Clearance of IND for MM-120 in Treatment of Generalized Anxiety Disorder

Go back to Mind Medicine (MNMD) Granted FDA Clearance of IND for MM-120 in Treatment of Generalized Anxiety Disorder

FDA Clears MindMed IND for MM-120 in Treatment of Generalized Anxiety Disorder

January 25, 2022 7:30 AM EST

NEW YORK, Jan. 25, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a clinical-stage biopharmaceutical company developing psychedelic-inspired therapies for the treatment of brain-based disorders, announced today that the U.S. Food and Drug Administration (FDA) has cleared MindMed's Investigational New Drug (IND) application, allowing the Company's Phase 2b dose-optimization trial of MM-120 for the treatment of generalized anxiety disorder (GAD) to proceed.

... More